Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ugur Coskun

Showing results (111-120 of 136) with videos related to

Pageof 14
Sort By:
Medical Oncology (Northwood, London, England)|February 27, 2009
Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancerAli Osman Kaya, Suleyman Buyukberber, Mustafa Benekli, et al.
Journal of the National Medical Association|September 1, 2009
Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancerUgur Coskun, Necati Alkis, Gokhan Celenkoglu, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 17, 2009
Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimensRamazan Yildiz, Mehmet Emin Kalender, Faysal Dane, et al.
Angiology|September 21, 2013
Relationship between increased serum resistin level and severity of coronary artery diseaseUmit Yasar Sinan, Ismail Polat Canbolat, Onur Baydar, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|March 5, 2009
Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown originAli Osman Kaya, Ugur Coskun, Mustafa Unlu, et al.
Journal of Chemotherapy (Florence, Italy)|October 9, 2012
The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimensAli Osman Kaya, Ugur Coskun, Mahmut Gumus, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|December 24, 2014
Outcome of 561 non-metastatic triple negative breast cancer patients: multi-center experience from TurkeyBurcin Budakoglu, Kadri Altundag, Sercan Aksoy, et al.
Journal of Chemotherapy (Florence, Italy)|October 12, 2013
Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO)Bulent Cetin, Mustafa Benekli, Ibrahim Turker, et al.
Onkologie|October 6, 2012
Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapyAli O Kaya, Ugur Coskun, Metin Ozkan, et al.
Journal of Cancer Research and Clinical Oncology|June 23, 2012
Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancerRamazan Yildiz, Mustafa Benekli, Metin Ozkan, et al.
Pageof 14

Showing results (111-120 of 136) with videos related to

Sort By:
Pageof 14
Medical Oncology (Northwood, London, England)|February 27, 2009
Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancerAli Osman Kaya, Suleyman Buyukberber, Mustafa Benekli, et al.
Journal of the National Medical Association|September 1, 2009
Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancerUgur Coskun, Necati Alkis, Gokhan Celenkoglu, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 17, 2009
Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimensRamazan Yildiz, Mehmet Emin Kalender, Faysal Dane, et al.
Angiology|September 21, 2013
Relationship between increased serum resistin level and severity of coronary artery diseaseUmit Yasar Sinan, Ismail Polat Canbolat, Onur Baydar, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|March 5, 2009
Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown originAli Osman Kaya, Ugur Coskun, Mustafa Unlu, et al.
Journal of Chemotherapy (Florence, Italy)|October 9, 2012
The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimensAli Osman Kaya, Ugur Coskun, Mahmut Gumus, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|December 24, 2014
Outcome of 561 non-metastatic triple negative breast cancer patients: multi-center experience from TurkeyBurcin Budakoglu, Kadri Altundag, Sercan Aksoy, et al.
Journal of Chemotherapy (Florence, Italy)|October 12, 2013
Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO)Bulent Cetin, Mustafa Benekli, Ibrahim Turker, et al.
Onkologie|October 6, 2012
Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapyAli O Kaya, Ugur Coskun, Metin Ozkan, et al.
Journal of Cancer Research and Clinical Oncology|June 23, 2012
Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancerRamazan Yildiz, Mustafa Benekli, Metin Ozkan, et al.
Pageof 14